Triplet with Ribociclib, AfINitor® and AI posT CDK4/6 Inhibitor
Novartis is recruiting men and postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer who have progressed on a cyclin-dependent kinase 4 and 6 inhibitor. By participating in these studies, you will receive an investigational drug called ribociclib (LEE011) in combination with everolimus and exemestane. All participants will receive care from a study team of health care professionals at a clinical study site. See more at: https://clinicaltrials.gov/ct2/show/NCT02732119
As with all clinical trials, you have the right to leave the study at any time, for any reason.